INS and type 1 diabetes mellitus: In addition, a recent study in newly diagnosed type 1 diabetes patients (mostly less than 18 years of age) treated with IL-1Ra (anakinra) and IL-1β (canakinumab) inhibitors revealed no major safety concerns although they failed to prevent deterioration of endogenous pancreatic insulin (C-peptide) secretion in these patients[36].